<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of bronchiolar disorders in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of bronchiolar disorders in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of bronchiolar disorders in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchiolitis is a general term used to describe a nonspecific inflammatory injury that primarily affects the
         <strong>
          small airways
         </strong>
         (eg, 2 mm or less in diameter without cartilage)  (
         <a class="graphic graphic_picture graphicRef74793" href="/z/d/graphic/74793.html" rel="external">
          picture 1
         </a>
         ), often sparing a considerable portion of the interstitium [
         <a href="#rid1">
          1-6
         </a>
         ].
        </p>
        <p>
         An overview of bronchiolar disorders in adults is provided here. The acute infectious bronchiolitis that occurs predominantly in young children and proliferative bronchiolitis, a component of organizing pneumonia (previously known as bronchiolitis obliterans organizing pneumonia [BOOP]) are described separately. (See
         <a class="medical medical_review" href="/z/d/html/6018.html" rel="external">
          "Bronchiolitis in infants and children: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6020.html" rel="external">
          "Bronchiolitis in infants and children: Treatment, outcome, and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3934302">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchiolitis is a broad histopathologic term that refers to inflammation, narrowing, or obliteration of bronchioles  (
         <a class="graphic graphic_table graphicRef101928" href="/z/d/graphic/101928.html" rel="external">
          table 1
         </a>
         ). The nomenclature of bronchiolitis has been confusing because clinicians and pathologists have sometimes used one term to describe different disease processes [
         <a href="#rid3">
          3,4,7-9
         </a>
         ]. The following are definitions of the various descriptors used in reference to bronchiolar disorders:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute bronchiolitis
         </strong>
         – Acute bronchiolitis is histologically characterized by intense inflammation of small bronchioles with associated epithelial necrosis and sloughing. Acute bronchiolitis is rare in adults but has been most commonly associated with infections and inhalational injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchiolitis obliterans
         </strong>
         – The term bronchiolitis obliterans (also called obliterative bronchiolitis) is used by clinicians to describe the clinical syndrome of dyspnea and airflow limitation not reversible with inhaled bronchodilator that is associated with small airways injury due to a spectrum of inhalational agents, infections, systemic diseases, chronic lung allograft dysfunction after lung transplantation, and graft versus host disease in hematopoietic cell transplantation  (
         <a class="graphic graphic_table graphicRef70650" href="/z/d/graphic/70650.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is typically associated with the histopathologic description of constrictive bronchiolitis (see below). However, in the older literature, pathologists used this term to describe intrabronchiolar polypoid protrusions that obliterate the lumen from within, what is now called proliferative bronchiolitis [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchiolitis obliterans syndrome (BOS)
         </strong>
         – Patients who have undergone lung transplantation or hematopoietic cell transplantation can develop bronchiolitis obliterans (BO). BOS is a clinical term that is used to describe airflow limitation that is a marker for BO in transplant recipients when the patient has not had confirmatory lung biopsy. Thus, following lung transplantation, the diagnosis of BOS can be made on the basis of new airflow limitation, without histologic confirmation. (See
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Constrictive bronchiolitis
         </strong>
         – Constrictive bronchiolitis is the histopathologic correlate of the clinical syndrome bronchiolitis obliterans and is characterized by fibroproliferative thickening of the bronchiolar walls causing narrowing of the bronchiolar lumen, which may progress to the complete obliteration of bronchioles.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proliferative bronchiolitis
         </strong>
         – Proliferative bronchiolitis is a distinct histopathologic pattern in which characteristic intraluminal fibrotic buds, called Masson bodies, extend beyond alveolar ducts to alveoli. When proliferative bronchiolitis is associated with extension of inflammatory cells into the more distal lung parenchyma, the process is called organizing pneumonia. The cryptogenic form of organizing pneumonia, previously called idiopathic bronchiolitis obliterans organizing pneumonia (BOOP) is discussed separately. (See
         <a class="local">
          'Proliferative bronchiolitis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Respiratory bronchiolitis
         </strong>
         – Respiratory bronchiolitis is seen predominantly in cigarette smokers and is associated with the characteristic finding of tan-pigmented macrophages in the respiratory bronchioles. Respiratory bronchiolitis is typically asymptomatic; when the process advances enough to cause symptoms and radiographic opacities, it is called respiratory bronchiolitis-associated interstitial lung disease (RB-ILD). (See
         <a class="local">
          'Respiratory bronchiolitis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4319.html" rel="external">
          "Respiratory bronchiolitis-associated interstitial lung disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cellular bronchiolitis
         </strong>
         – Cellular bronchiolitis is a pathologic term that refers to the presence of an inflammatory cell infiltrate (eg, lymphocytes, neutrophils, eosinophils) involving the bronchioles. Follicular bronchiolitis, respiratory bronchiolitis, and diffuse panbronchiolitis are forms of cellular bronchiolitis. Cellular bronchiolitis can also be seen in association with diseases such as hypersensitivity pneumonitis, granulomatosis with polyangiitis, and asthma.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H48749157">
         <span class="h1">
          BRONCHIOLITIS OBLITERANS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchiolitis obliterans, also known as obliterative bronchiolitis, refers to the clinical syndrome associated with small airways injury caused by a spectrum of inhalational, infectious, and drug exposures, and also following lung or hematopoietic cell transplantation  (
         <a class="graphic graphic_table graphicRef101928" href="/z/d/graphic/101928.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. The clinical syndrome is typically characterized by dyspnea, airflow limitation that is not reversible by inhaled bronchodilator, and a chest radiograph that shows normal or hyperinflated lungs. Histopathologically, bronchiolitis obliterans is associated with constrictive bronchiolitis, and the two terms are sometimes used interchangeably in the literature. (See
         <a class="local">
          'Histopathology'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most instances, the pathogenesis of bronchiolitis remains poorly defined. Injury to the bronchiolar epithelium appears to initiate the process  (
         <a class="graphic graphic_figure graphicRef70237" href="/z/d/graphic/70237.html" rel="external">
          figure 1
         </a>
         ). The alveoli immediately adjacent to the small airways are also frequently involved. The repair process may result in complete recovery or may be characterized by excessive proliferation of granulation tissue that causes narrowing or obliteration of the airway lumen. In some cases, fibrosis is primarily submucosal and peribronchiolar in distribution, resulting in extrinsic narrowing or obliteration of the bronchiolar lumen.
        </p>
        <p class="headingAnchor" id="H3934638">
         <span class="h2">
          Causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         A broad range of agents and disease processes can cause lung injury that leads to bronchiolitis obliterans  (
         <a class="graphic graphic_table graphicRef70650" href="/z/d/graphic/70650.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid3">
          3,10-31
         </a>
         ]. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhalational injury
         </strong>
         – Inhalation of toxins and irritants, including nitrogen oxides, ammonia, chlorine, welding fumes, volatile food flavorings (eg, diacetyl), volatile organic compounds, ultra-fine particles, vitamin E acetate, mineral or heavy metal dusts, free-base cocaine, and other chemicals via vaping may result in small airway injury. For example, soldiers deployed to the 1991 Gulf War and the post-9/11 conflicts in Iraq and Afghanistan who experienced exposure to airborne hazards (including sandstorms, burn pits, and improvised explosive devices) are at risk for bronchiolitis obliterans.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – Infections including respiratory syncytial virus, adenovirus, influenza, parainfluenza, or
         <em>
          Mycoplasma pneumoniae
         </em>
         have been linked to small airway disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reactions to pharmaceuticals
         </strong>
         –Inflammatory reactions to systemic administration of pharmacologic agents including
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         , gold,
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          penicillamine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         may rarely result in bronchiolitis obliterans.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Manifestation of systemic disease
         </strong>
         – Bronchiolitis obliterans may arise in association with systemic diseases including graft-versus-host disease (GVHD) in lung and hematopoietic cell transplantation, rheumatoid arthritis, Sjögren's disease, as well as, rarely, ulcerative colitis/primary biliary cholangitis and paraneoplastic pemphigus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Idiopathic
         </strong>
         – Bronchiolitis obliterans may arise without known cause, also referred to as cryptogenic bronchiolitis obliterans.
        </p>
        <p>
        </p>
        <p>
         (See
         <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">
          "Overview of pleuropulmonary diseases associated with rheumatoid arthritis", section on 'Airway obstruction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Airflow obstruction and bronchiolitis obliterans'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">
          "Paraneoplastic pemphigus", section on 'Pulmonary disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3934624">
         <span class="h2">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of constrictive bronchiolitis usually include dyspnea and cough, sometimes with sputum production. Symptoms are generally slowly progressive over weeks to months [
         <a href="#rid3">
          3,4,27
         </a>
         ]. Among patients with rheumatoid arthritis, symptoms typically follow the onset of joint symptoms by several years (mean 9.5 ± 10 years), although they may precede or present concomitantly with the diagnosis in approximately 10 percent [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         On examination, tachypnea, crackles, and/or wheezing may be present.
        </p>
        <p class="headingAnchor" id="H3934583">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         When bronchiolitis obliterans is suspected based on symptoms of cough and dyspnea that are not well-explained by asthma or COPD, the most helpful tests are chest imaging, usually a high-resolution computed tomography (HRCT) scan with inspiratory and expiratory images and pulmonary function testing with diffusing capacity and ambulatory oximetry.
        </p>
        <p>
         The evaluation of possible bronchiolitis obliterans in patients who have undergone lung or hematopoietic transplantation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Evaluation for CLAD'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3934601">
         <span class="h3">
          Pulmonary function testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary function testing (PFT) is helpful for excluding other diagnostic possibilities, providing support for the diagnosis of bronchiolitis, and defining the severity of disease. In bronchiolitis obliterans, spirometry may be normal or show obstructive changes with air trapping, but without reversibility following inhaled bronchodilator [
         <a href="#rid4">
          4,16,17
         </a>
         ]. Given the vast number of bronchioles, a large percentage can be narrowed or obstructed before a significant loss of function occurs [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         .)
        </p>
        <p>
         Lung volumes often show air trapping (eg, increased residual volume and functional residual capacity), but occasionally, show a mixed pattern of obstruction and restriction [
         <a href="#rid33">
          33
         </a>
         ] or restriction alone [
         <a href="#rid34">
          34
         </a>
         ]. The restriction is probably related to the proportion of airways that are fully obstructed.
        </p>
        <p>
         The diffusing capacity for carbon monoxide (DLCO) is usually reduced, particularly as the disease progresses [
         <a href="#rid3">
          3,35
         </a>
         ]. In a case series of soldiers with constrictive bronchiolitis (bronchiolitis obliterans), the most common abnormality on PFT was a reduced DLCO [
         <a href="#rid17">
          17
         </a>
         ]. Resting hypoxemia is frequently present. (See
         <a class="medical medical_review" href="/z/d/html/6972.html" rel="external">
          "Diffusing capacity for carbon monoxide"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3936193">
         <span class="h3">
          Chest imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases of chronic bronchiolitis, the plain chest radiograph is normal or shows only increased bronchial wall thickening or hyperinflation (without marked flattening of the diaphragms or hyperlucent areas that would suggest emphysema).
        </p>
        <p>
         HRCT is more likely to identify findings consistent with bronchiolitis than plain chest radiographs, particularly when inspiratory and expiratory HRCT images are obtained  (
         <a class="graphic graphic_table graphicRef101928" href="/z/d/graphic/101928.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid36">
          36-39
         </a>
         ]. The most consistent abnormalities on HRCT are expiratory air trapping (mosaic or diffuse) and bronchial wall thickening (eg, nodules and "v" or "y" shaped branching linear opacities). The nodules are centrilobular, consistent with the anatomic location of bronchioles. In addition, ground glass opacity in a mosaic pattern of attenuation is seen in some patients; the mosaic attenuation may be enhanced on expiratory views due to air trapping [
         <a href="#rid35">
          35
         </a>
         ]. Except for a mosaic pattern of attenuation, which is highly suggestive of bronchiolitis obliterans, it is often difficult to distinguish severe asthma from bronchiolitis [
         <a href="#rid36">
          36,40
         </a>
         ].
        </p>
        <p>
         Cylindric bronchial dilation or bronchiectasis can be seen with bronchiolitis obliterans, particularly in cases related to transplantation, rheumatic disease, inhalation of toxic fumes, and previous infection [
         <a href="#rid38">
          38
         </a>
         ]. Subpleural distribution of patchy consolidation or ground glass density is a characteristic finding of proliferative bronchiolitis on HRCT. Well or poorly-defined nodules on CT scans may correlate with areas of organizing pneumonia [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Rarely, diffuse cystic lung diseases has been reported in patients with evidence of chronic cellular or constrictive bronchiolitis on surgical lung biopsy [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3936224">
         <span class="h3">
          Bronchoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Findings on bronchoscopy and bronchoalveolar lavage in bronchiolitis obliterans are nonspecific. However, bronchoscopy can be helpful in identifying features suggestive of other disease processes in the differential diagnosis, such as the high bronchoalveolar lavage lymphocyte counts in hypersensitivity pneumonitis or endobronchial nonnecrotizing granulomas in airway sarcoid. In addition, bronchoalveolar lavage (BAL) can help diagnose infection or other etiologies as a cause of deteriorating lung function. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage"
         </a>
         .)
        </p>
        <p>
         Transbronchial lung biopsies generally yield insufficient tissue to make a diagnosis of bronchiolitis obliterans, as the histopathologic findings are subtle and patchy, although they may help exclude other processes [
         <a href="#rid1">
          1,42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Transbronchial lung biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3936390">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of bronchiolitis obliterans should be considered in patients who present with insidious onset of dyspnea and cough, especially when the symptoms and signs do not follow a typical pattern for asthma or COPD. As an example, bronchiolitis should be considered in a nonsmoker when airflow limitation is irreversible or associated with a gas transfer abnormality.
        </p>
        <p>
         The clinical setting may also alert the clinician to suspect bronchiolitis; for example, recent toxic fume exposure, symptoms of viral infection, history of organ transplantation, or concomitant rheumatic disease. (See
         <a class="local">
          'Causes'
         </a>
         above.)
        </p>
        <p>
         A firm diagnosis of bronchiolitis obliterans usually requires a lung biopsy, although in a high probability clinical setting such as a known predisposing inhalational exposure or hematopoietic cell or lung transplantation (see
         <a class="local">
          'Causes'
         </a>
         above), the combination of airflow limitation on spirometry and HRCT showing expiratory air trapping (mosaic or diffuse), bronchial wall thickening, and centrilobular nodules may be sufficient to make the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Airflow obstruction and bronchiolitis obliterans'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H713172900">
         <span class="h3">
          Lung biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         An open or thoracoscopic lung biopsy is required to make a definitive diagnosis, although tissue confirmation may not be necessary in patients with a clear predisposition and typical HRCT. A multidisciplinary discussion can help guide the decision-making, balancing the benefit of a clear diagnosis with potential risk of the procedure. Transbronchial lung biopsy is often
         <strong>
          inadequate
         </strong>
         for diagnosis because the disease is patchy and involves the respiratory and membranous bronchioles but may be helpful in excluding alternate diagnostic possibilities. (See
         <a class="local">
          'Bronchoscopy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H713172906">
         <span class="h3">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histopathologic lesions of bronchiolitis obliterans are often subtle, and specific attention must be placed on examining the small airways. This may include step sectioning of the tissue and using special stains (elastic stains) to identify remnants of the small airway walls. Constrictive bronchiolitis, the histopathologic lesion most commonly seen following inhalation injury, is characterized by alterations in the walls of membranous and respiratory bronchioles, often without extensive changes in alveolar ducts and alveolar walls [
         <a href="#rid7">
          7,17
         </a>
         ]. These changes lead to concentric narrowing or complete obliteration of the airway lumen  (
         <a class="graphic graphic_picture graphicRef75444" href="/z/d/graphic/75444.html" rel="external">
          picture 2
         </a>
         ). The associated lesions comprise a spectrum of abnormalities that can include [
         <a href="#rid3">
          3,9,43
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subtle cellular infiltrates (predominantly T lymphocytes) around the small airways
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bronchiolar smooth muscle hypertrophy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bronchiolectasia with mucus stasis, distortion, and fibrosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total obliterative bronchiolar scarring  (
         <a class="graphic graphic_picture graphicRef62630" href="/z/d/graphic/62630.html" rel="external">
          picture 3
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Patients with predominant histopathologic features of constrictive bronchiolitis may have concomitant, but less frequent lesions of proliferative bronchiolitis [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="local">
          'Proliferative bronchiolitis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3936181">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of bronchiolitis obliterans includes severe asthma, COPD, hypersensitivity pneumonitis, sarcoidosis, and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aspiration-related bronchiolitis
         </strong>
         – The diagnosis of aspiration as a cause of small airway injury can be difficult. If untreated, chronic aspiration may result in permanent lung injury with fibrosis and bronchiectasis. Conditions associated with increased risk for aspiration include gastroesophageal reflux disease, neurologic conditions, head and neck cancer, prior irradiation, gastric surgery, and esophageal abnormalities such as dysmotility or hiatal hernia [
         <a href="#rid39">
          39,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asthma
         </strong>
         – Asthma is typically differentiated from bronchiolitis obliterans by the presence of reversible airflow limitation on spirometry. However, severe asthma can be associated with a component of irreversible airflow limitation. A reduction in diffusing capacity is uncommon in asthma, but common in bronchiolitis. While mosaic attenuation may rarely be seen in asthma, it is present in approximately 50 percent of patients with bronchiolitis obliterans. (See
         <a class="local">
          'Chest imaging'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/543.html" rel="external">
          "Asthma in adolescents and adults: Evaluation and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A few patients with clinical features of severe asthma have been found to have hypereosinophilic obliterative bronchiolitis. These patients are poorly responsive to inhaled glucocorticoids, have eosinophilia in the peripheral blood (≥1000 cells/microL) and bronchoalveolar lavage (&gt;25 percent), and an HRCT that is more consistent with bronchiolitis obliterans than asthma. (See
         <a class="medical medical_review" href="/z/d/html/564.html" rel="external">
          "Evaluation of severe asthma in adolescents and adults", section on 'Assessing conditions that mimic asthma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As asthma is common, individual patients with bronchiolitis obliterans may have a component of asthma and have a clinical response to inhaled bronchodilators.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          COPD
         </strong>
         – Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation on spirometry that is irreversible or incompletely reversible. Most patients have a significant cigarette smoking history and lack exposure to the typical etiologic agents for bronchiolitis obliterans. While respiratory bronchiolitis is a common finding among cigarette smokers, it is usually asymptomatic, unless it progresses to respiratory bronchiolitis-interstitial lung disease (RB-ILD). (See
         <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">
          "Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Diagnosis'
         </a>
         and
         <a class="local">
          'Respiratory bronchiolitis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypersensitivity pneumonitis
         </strong>
         – Hypersensitivity pneumonitis, while typically associated with restrictive physiology, can cause small airways narrowing due to compression by epithelial and subepithelial granulomas. The history of exposure to organic dusts or other typical causes of hypersensitivity pneumonitis is a main differentiator from bronchiolitis obliterans. In hypersensitivity pneumonitis, histopathology demonstrates mononuclear cell infiltration and poorly-formed granulomas in the walls of bronchioles, in addition to the interstitial infiltration with lymphocytes [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4309.html" rel="external">
          "Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Epidemiology, causes, and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">
          "Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sarcoidosis
         </strong>
         – Sarcoidosis can have a similar presentation in terms of cough and dyspnea and, on occasion, airway sarcoid is associated with airflow limitation. More commonly, sarcoidosis is associated with a restrictive pattern (reduced vital capacity and total lung capacity) and a reduction in the DLCO; it is also not unusual for lung function to be normal. A lung or mediastinal lymph node biopsy showing well-formed, noncaseating granulomas would make sarcoidosis much more likely. (See
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchocentric granulomatosis
         </strong>
         – Bronchocentric granulomatosis predominantly affects the bronchi, but bronchiolar inflammation may be present. Identification of fungal hyphae associated with granulomatous inflammation on bronchial biopsy would strongly support the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/4322.html" rel="external">
          "Bronchocentric granulomatosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)
         </strong>
         – DIPNECH is a generalized proliferation of pulmonary neuroendocrine cells that can be confined to the mucosa of the airways, invade locally to form "tumorlets," or develop into invasive neuroendocrine tumors (NETs; carcinoid tumors). The tumorlets are intimately related to an airway and are ≤5 mm in diameter. DIPNECH is considered a preinvasive precursor to pulmonary NETs. (See
         <a class="medical medical_review" href="/z/d/html/4883.html" rel="external">
          "Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging", section on 'Classification, histology, and histochemistry'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         DIPNECH is predominantly seen in women and typically presents with cough and dyspnea, airflow limitation on spirometry, and multiple small nodules (4 to 10 mm) on computed tomography (CT) [
         <a href="#rid46">
          46-49
         </a>
         ]. In one series of 30 patients with DIPNECH, 44 percent had associated constrictive bronchiolitis [
         <a href="#rid46">
          46
         </a>
         ]. Serum chromogranin A levels may be elevated. Mosaic attenuation with multiple small nodules on chest CT is suggestive of DIPNECH [
         <a href="#rid50">
          50
         </a>
         ]. The diagnosis is usually made by lung biopsy: transbronchial (showing pulmonary neuroendocrine cells), transbronchial cryobiopsy, or surgical. (See
         <a class="medical medical_review" href="/z/d/html/4883.html" rel="external">
          "Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most patients with DIPNECH remain stable for many years. The optimal treatment for patients who have progressive disease remains unclear. Various options are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/85914.html" rel="external">
          "Lung neuroendocrine (carcinoid) tumors: Treatment and prognosis", section on 'Management of patients with DIPNECH'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypereosinophilic obliterative bronchiolitis
         </strong>
         – A small number of patients with clinical features of severe asthma have been found to have hypereosinophilic obliterative bronchiolitis. Differentiating characteristics of this condition include a peripheral blood eosinophil count ≥1000 cells/microL (1 x 10
         <sup>
          9
         </sup>
         /L) and/or bronchoalveolar lavage eosinophils &gt;25 percent; persistent airflow obstruction with a post bronchodilator forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) &lt;80 percent predicted and an FEV
         <sub>
          1
         </sub>
         /forced vital capacity (FVC) &lt;70 percent not improved after four to six weeks of high dose inhaled glucocorticoids; and a lung biopsy showing prominent bronchiolar wall infiltration by eosinophils and/or HRCT features of bronchiolitis. (See
         <a class="medical medical_review" href="/z/d/html/564.html" rel="external">
          "Evaluation of severe asthma in adolescents and adults", section on 'Assessing conditions that mimic asthma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other bronchiolar disorders
         </strong>
         – Other bronchiolar disorders, such as airway-centered interstitial fibrosis (ACIF) and diffuse panbronchiolitis, can present similarly  (
         <a class="graphic graphic_table graphicRef101928" href="/z/d/graphic/101928.html" rel="external">
          table 1
         </a>
         ). ACIF is differentiated from bronchiolitis obliterans based on the pathology, and diffuse panbronchiolitis typically has concomitant symptoms of sinusitis and productive cough, in addition to different histopathologic features, as described below. (See
         <a class="local">
          'Airway-centered interstitial fibrosis'
         </a>
         below and
         <a class="local">
          'Diffuse panbronchiolitis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3935757">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal treatment for bronchiolitis obliterans (constrictive type) is not known, and data in support of the various options are limited. In a portion of patients, the disease is progressive despite all therapies and eventuates in respiratory failure. Other patients may not improve with therapy, but may have stable lung function over several years [
         <a href="#rid51">
          51
         </a>
         ]. Thus, the decision to initiate therapy is often based on the severity of respiratory impairment and evidence of disease progression. When an underlying disease process is present, this may also influence treatment decisions. Unfortunately, bronchiolitis obliterans tends to be relatively refractory to therapy. The following represents our approach.
        </p>
        <p>
         The treatment of bronchiolitis obliterans in the setting of lung or hematopoietic cell transplantation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Treatment of BOS'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Airflow obstruction and bronchiolitis obliterans'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H192358484">
         <span class="h3">
          Symptom-based and supportive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         General measures to reduce symptoms include inhaled bronchodilators and cough suppressants (eg,
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         ,
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         ), guided by symptomatic response and supplemental oxygen as needed to maintain the pulse oxygen saturation ≥89 percent. In addition, inhaled bronchodilators may be of benefit for dyspnea if the patient has a component of reversible airways obstruction. (See
         <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">
          "Long-term supplemental oxygen therapy", section on 'Indications'
         </a>
         .)
        </p>
        <p>
         Supportive therapies that are helpful in other chronic lung diseases are advisable, such as smoking cessation (if needed), pulmonary rehabilitation, and vaccination against influenza and pneumococcus. (See
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">
          "Pneumococcal vaccination in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H192358428">
         <span class="h3">
          Cessation of culprit drugs and exposures
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients taking a medication that has been associated with bronchiolitis obliterans, cessation of that medication is recommended although at times it is not clear whether the drug or the disease for which the drug is taken (eg, rheumatoid arthritis) is actually the culprit. In small series of workers exposed to food flavoring fumes (eg, diacetyl used in popcorn and other foods), cessation of exposure was associated with disease stabilization in some workers, although others have experienced progressive disease [
         <a href="#rid11">
          11,34,52
         </a>
         ]. For patients with vaping-associated disease, it has also been reported that cessation of vaping can improve symptoms, with variable impact on lung function and imaging [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H109741405">
         <span class="h3">
          Pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Macrolide antibiotics, systemic glucocorticoids, and immunosuppressive agents have been associated with benefit in isolated patients, but responses are variable.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Macrolide antibiotics
         </strong>
         – Macrolide antibiotics are increasingly used in the long-term management of nontransplant-related bronchiolitis obliterans because of their success in diffuse panbronchiolitis [
         <a href="#rid42">
          42,53-55
         </a>
         ]. For patients with cryptogenic bronchiolitis obliterans that is symptomatic, we suggest a three- to six-month trial of a macrolide antibiotic, such as a low oral dose of
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         (200 to 600 mg/day),
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         (250 mg/day), or
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         (250 or 500 mg/day). Patients whose lung function stabilizes or improves can continue on long-term therapy. (See
         <a class="medical medical_review" href="/z/d/html/4366.html" rel="external">
          "Diffuse panbronchiolitis", section on 'Macrolide antibiotics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Macrolide therapy has not been formally assessed in patients with bronchiolitis obliterans due to rheumatic disease or inhalational exposures (eg, diacetyl flavoring agents), but a similar trial of macrolide therapy may be reasonable in these patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The effect of macrolides may be influenced by the underlying disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a series of 19 patients with bronchiolitis obliterans not related to transplantation, but including rheumatic diseases, 53 percent were treated with macrolide antibiotics; long-term follow-up revealed overall stability in lung function [
         <a href="#rid51">
          51
         </a>
         ]. The associated literature review, which included an additional 104 patients, found a lower rate of macrolide use and greater mortality, providing some additional support for macrolide use.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a report that included seven patients with cryptogenic bronchiolitis obliterans, none of the patients improved with macrolides, although the dose and duration of therapy were not given [
         <a href="#rid27">
          27
         </a>
         ]. In the same report, pulmonary function did not improve with macrolides in five patients with rheumatoid arthritis. One patient with bronchiolitis obliterans that developed after exposure to dust at the World Trade Center improved with long-term
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The role of macrolide antibiotics in lung and hematopoietic cell transplant-related BOS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Treatment of BOS'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Airflow obstruction and bronchiolitis obliterans'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoids
         </strong>
         – The rationale behind glucocorticoid and immunosuppressive therapy comes from the histopathologic identification of lymphocytic infiltrates and the association with diseases such as rheumatoid arthritis that tend to respond to these agents. However, the role and efficacy of systemic glucocorticoid therapy in
         <strong>
          nontransplant
         </strong>
         and nonrheumatic disease-related bronchiolitis obliterans is unclear. We typically reserve systemic glucocorticoids for patients with persistent symptoms and progressive deterioration in lung function. If a trial of glucocorticoids (eg, four to six weeks) does not lead to improvement in lung function, we taper and discontinue glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most case series of the constrictive type of bronchiolitis obliterans have not shown improvement with systemic glucocorticoids [
         <a href="#rid27">
          27,32,43,57
         </a>
         ]. In a case series that included long-term follow-up of five patients with rheumatoid arthritis associated bronchiolitis obliterans and seven patients with cryptogenic bronchiolitis obliterans, none of the patients exhibited significant improvement with glucocorticoids, although only one patient experienced progressive respiratory impairment [
         <a href="#rid27">
          27
         </a>
         ]. In a separate series of cryptogenic bronchiolitis obliterans, four patients were treated with oral glucocorticoids; none experienced improvement, although all had stable disease over one to five years [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similarly, systemic glucocorticoids have not been of benefit in bronchiolitis obliterans associated with food flavoring (diacetyl)-associated bronchiolitis obliterans [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with clinical features that overlap with asthma or a prior diagnosis of asthma (eg, partial response to bronchodilators), a trial of systemic or inhaled glucocorticoids following guidelines for asthma is reasonable. (See
         <a class="medical medical_review" href="/z/d/html/547.html" rel="external">
          "An overview of asthma management", section on 'Initiating pharmacologic treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         High-dose glucocorticoids are typically part of the treatment of hematopoietic cell transplantation-related BOS, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/3550.html" rel="external">
          "Treatment of chronic graft-versus-host disease", section on 'Prednisone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Chronic therapy with systemic glucocorticoids is associated with a number of adverse effects. Steps to monitor, prevent, and treat these side effects are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional immunosuppressive therapy
         </strong>
         – While immunosuppressive therapy has been used in patients with bronchiolitis obliterans based on the histopathologic pattern and the association with rheumatic disease in some patients, clear benefit has not been demonstrated. Thus, we avoid cytotoxic immunosuppressive agents in patients with nontransplant related bronchiolitis obliterans, unless these agents are indicated to treat the underlying disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of cytotoxic immunosuppressive therapy (eg,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ) has been described in patients with rheumatoid arthritis [
         <a href="#rid27">
          27,32
         </a>
         ] and food flavoring related bronchiolitis obliterans [
         <a href="#rid52">
          52
         </a>
         ]. Other than the post-transplant experience, cytotoxic immunosuppressive agents have not been associated with significant improvement in lung function [
         <a href="#rid27">
          27,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The tumor necrosis factor-alpha (TNF-alpha) inhibitors,
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         and
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         , have been suggested as possible treatment for bronchiolitis obliterans associated with rheumatoid arthritis and Sjögren's disease, although results are conflicting [
         <a href="#rid27">
          27,58
         </a>
         ]. It is not known whether TNF-alpha inhibitors would be beneficial in other forms of bronchiolitis obliterans. (See
         <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">
          "Overview of pleuropulmonary diseases associated with rheumatoid arthritis", section on 'Obliterative bronchiolitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with bronchiolitis obliterans syndrome following lung or hematopoietic cell transplantation, intensification of immunosuppression is sometimes successful in reversing or stabilizing bronchiolitis obliterans syndrome based on case series. The management of bronchiolitis obliterans syndrome following transplantation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Treatment of BOS'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Airflow obstruction and bronchiolitis obliterans'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antireflux therapy
         </strong>
         – Gastroesophageal reflux disease (GERD) is prevalent in lung transplantation recipients, and non-acid reflux has been associated with the development of bronchiolitis obliterans syndrome [
         <a href="#rid59">
          59-63
         </a>
         ]. Aggressive therapy for GERD, possibly including surgery, has been proposed to prevent progression of lung transplant-related bronchiolitis obliterans syndrome, although additional studies are needed [
         <a href="#rid64">
          64
         </a>
         ]. Whether antireflux therapy has a role in nontransplant bronchiolitis obliterans has not been formally examined. (See
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Etiology and risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H192358562">
         <span class="h3">
          Lung transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         From 1995 to 2018, approximately 1 percent of primary lung transplantations were for bronchiolitis obliterans [
         <a href="#rid65">
          65
         </a>
         ]. General guidelines for lung transplantation and outcomes are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">
          "Lung transplantation: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">
          "Lung transplantation: General guidelines for recipient selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H713172470">
         <span class="h1">
          ACUTE BRONCHIOLITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute infectious bronchiolitis in adults has been reported in patients with
         <em>
          Mycoplasma pneumoniae
         </em>
         , respiratory syncytial virus, measles, influenza, pertussis, parainfluenza, and adenovirus [
         <a href="#rid3">
          3,66-69
         </a>
         ]. The clinical presentation of bronchiolitis in adults is poorly defined. Generally, an upper respiratory illness precedes onset of lower respiratory symptoms of cough, dyspnea on exertion, fever, tachypnea, and wheezing [
         <a href="#rid3">
          3
         </a>
         ]. In one series, computed tomography (CT) showed bronchial wall thickening, centrilobular nodules, and/or a tree-in-bud pattern [
         <a href="#rid68">
          68
         </a>
         ]. The diagnosis is generally clinical, based on the setting and imaging results. Treatment is largely supportive or, when available, directed at the underlying disease (eg, Mycoplasma, influenza). Occasionally, this acute syndrome has been reported to progress to bronchiolitis obliterans. (See
         <a class="medical medical_review" href="/z/d/html/6989.html" rel="external">
          "
          <i>
           Mycoplasma pneumoniae
          </i>
          infection in adults", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">
          "Seasonal influenza in nonpregnant adults: Treatment"
         </a>
         and
         <a class="local">
          'Bronchiolitis obliterans'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3935023">
         <span class="h1">
          PROLIFERATIVE BRONCHIOLITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Proliferative bronchiolitis is a histopathologic finding characterized by a more cellular appearance than bronchiolitis obliterans with fibroblast proliferation and an organizing intraluminal exudate that occludes bronchioles from within. The characteristic intraluminal fibrotic buds, called Masson bodies, are seen in the respiratory bronchioles; when they extend beyond alveolar ducts to alveoli, the term organizing pneumonia is used. It is more common than constrictive bronchiolitis and is seen in association with many pulmonary disorders  (
         <a class="graphic graphic_table graphicRef101928" href="/z/d/graphic/101928.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Proliferative bronchiolitis is particularly extensive or prominent in patients with cryptogenic organizing pneumonitis (COP), previously called idiopathic bronchiolitis obliterans with organizing pneumonia (idiopathic BOOP). In COP, Masson bodies extend to the alveoli and may extend from one alveolus to another through the pores of Kohn  (
         <a class="graphic graphic_picture graphicRef60476" href="/z/d/graphic/60476.html" rel="external">
          picture 4
         </a>
         ). Inflammatory changes in the surrounding alveolar walls and prominent foamy macrophages in alveolar spaces (ie, organizing pneumonia) are commonly present in COP. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia"
         </a>
         .)
        </p>
        <p>
         Proliferative bronchiolitis can also be seen as a minor feature of other interstitial lung diseases, such as chronic eosinophilic pneumonia, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, and nonspecific interstitial pneumonia.
        </p>
        <p>
         The high-resolution computed tomography (HRCT) findings of proliferative bronchiolitis include patchy air-space consolidation, ground-glass opacities, and small nodular opacities in the periphery and lower lung zones. When proliferative bronchiolitis is the predominant histopathologic finding, the next step is to determine whether the patient has organizing pneumonia that is cryptogenic or due to another process (secondary organizing pneumonia)  (
         <a class="graphic graphic_table graphicRef87710" href="/z/d/graphic/87710.html" rel="external">
          table 3
         </a>
         ). Proliferative bronchiolitis is typically responsive to glucocorticoids; the specific treatment regimen depends on the clinical features and underlying cause. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3935148">
         <span class="h1">
          FOLLICULAR BRONCHIOLITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Follicular bronchiolitis is characterized by lymphoid hyperplasia of bronchus-associated lymphoid tissue (BALT) [
         <a href="#rid36">
          36,70
         </a>
         ]. Most cases of follicular bronchiolitis are associated with rheumatic diseases (particularly rheumatoid arthritis and Sjögren's disease), immunodeficiency (eg, HIV infection and acquired immunoglobulin deficiency), or hypersensitivity pneumonitis [
         <a href="#rid71">
          71-76
         </a>
         ]. Follicular bronchiolitis can also be seen in the context of lymphoid interstitial pneumonia and diffuse panbronchiolitis [
         <a href="#rid9">
          9
         </a>
         ]. It is rare for follicular bronchiolitis to present in the absence of one of these predisposing processes. (See
         <a class="medical medical_review" href="/z/d/html/4361.html" rel="external">
          "Lymphoid interstitial pneumonia", section on 'Pathologic findings'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4366.html" rel="external">
          "Diffuse panbronchiolitis", section on 'Pathology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">
          "Overview of pleuropulmonary diseases associated with rheumatoid arthritis", section on 'Follicular bronchiolitis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4301.html" rel="external">
          "Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis", section on 'Follicular bronchiolitis'
         </a>
         .)
        </p>
        <p>
         Patients present with progressive dyspnea, and the high-resolution computed tomography (HRCT) typically shows centrilobular and peribronchial nodules 1 to 12 mm in diameter [
         <a href="#rid77">
          77,78
         </a>
         ]. The tree-in-bud pattern may be present. Areas of ground glass opacity and, rarely, bronchial dilation and interlobular septal thickening may be present [
         <a href="#rid36">
          36,77
         </a>
         ]. Thin-walled cysts may also be seen (especially in patients with concomitant lymphocytic interstitial pneumonia); they are thought to be due to check-valve obstruction of small bronchioles by lymphatic tissue [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         The diagnosis of follicular bronchiolitis is based on a lung biopsy that shows hyperplastic lymphoid follicles with reactive germinal centers distributed along the bronchioles. Sometimes, follicular bronchiolitis is a minor feature in patients with other interstitial lung diseases, such as nonspecific interstitial pneumonia and organizing pneumonia [
         <a href="#rid9">
          9,74
         </a>
         ]. If peribronchiolar granulomas are noted, the possibility of sarcoidosis (tightly formed granulomas), granulomatosis with polyangiitis (necrotizing granulomas), or hypersensitivity pneumonitis (poorly-formed granulomas) should be explored.
        </p>
        <p>
         Follicular bronchiolitis is usually treated as part of the underlying disease, whether it is associated with a rheumatic disease or immunodeficiency [
         <a href="#rid1">
          1,36,79
         </a>
         ]. Anecdotal success with macrolide antibiotics and systemic glucocorticoids has been reported in primary follicular bronchiolitis [
         <a href="#rid78">
          78,80,81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H48749398">
         <span class="h1">
          RESPIRATORY BRONCHIOLITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory bronchiolitis is a well-recognized pathological lesion found in the lungs of many cigarette smokers that is usually asymptomatic. It is recognized by a characteristic finding of tan-pigmented macrophages in the respiratory bronchioles. These intraluminal macrophages are accompanied by a patchy submucosal and peribronchiolar infiltrate of lymphocytes and histiocytes. Peribronchiolar fibrosis extends in a stellate pattern into contiguous alveolar walls. More severe, symptomatic disease generally reflects more extensive interstitial involvement and is called respiratory bronchiolitis-associated interstitial lung disease (RB-ILD). On high-resolution computed tomography (HRCT), RB-ILD is associated with diffuse or patchy ground glass opacities in a mosaic pattern or fine nodules and air trapping. RB typically resolves with smoking cessation. The diagnosis and management of RB-ILD is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4319.html" rel="external">
          "Respiratory bronchiolitis-associated interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3935354">
         <span class="h1">
          AIRWAY-CENTERED INTERSTITIAL FIBROSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Airway-centered interstitial fibrosis (ACIF), also called idiopathic bronchiolocentric interstitial pneumonia or chronic bronchiolitis with fibrosis, is a form of bronchiolitis in which the key histopathologic finding is a centrilobular and bronchiolocentric inflammatory infiltrate with peribronchiolar fibrosis and an absence of granulomas [
         <a href="#rid82">
          82-85
         </a>
         ]. Prominent epithelial hyperplasia involving adjacent alveolar septa is usually present. Goblet cell metaplasia, squamous metaplasia, and necrosis have also been described. Many of the cases were thought to be characteristic of hypersensitivity pneumonitis (HP) on clinical grounds, although no specific antigens were identified.
        </p>
        <p>
         Many of the reported patients had a history of smoking, raising concerns that cigarette smoking may be a contributor to airway injury. Chronic silent microaspiration and toxic or hypersensitivity reactions may contribute to the development of this pattern of injury in some patients [
         <a href="#rid84">
          84-86
         </a>
         ].
        </p>
        <p>
         The typical patient is a middle-aged woman (40 to 50 years old) with a chronic nonproductive cough [
         <a href="#rid87">
          87
         </a>
         ]. The clinical course is more rapidly progressive than that of most patients with HP, nonspecific interstitial pneumonia (NSIP), or respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), the other diagnoses that have a similar presentation.
        </p>
        <p>
         Both restrictive and obstructive patterns may be found on lung function testing. High-resolution computed tomography (HRCT) scans of airway-centered interstitial fibrosis show a combination of peribronchovascular ground glass opacities, traction bronchiectasis, and thickening of bronchial walls. Bronchial wall thickening is characteristic of more advanced peribronchiolar fibrosis [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Unlike HP, the percentage of lymphocytes on bronchoalveolar lavage is less than 40 percent [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         The diagnosis of ACIF is based upon lung biopsy showing the above-described findings. The optimal treatment is not known. In some patients, the disease appears to stabilize or improve during treatment with systemic or inhaled glucocorticoid; however, the disease has progressed despite glucocorticoid treatment in about half of the patients reported [
         <a href="#rid44">
          44,84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2426762019">
         <span class="h1">
          HYPEREOSINOPHILIC OBLITERATIVE BRONCHIOLITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypereosinophilic obliterative bronchiolitis (HOB) is a rare, poorly-characterized cause of chronic irreversible airflow obstruction that is associated with blood or bronchoalveolar lavage eosinophilia and bronchiolar nodules on high-resolution computed tomography (HRCT) imaging [
         <a href="#rid88">
          88,89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/564.html" rel="external">
          "Evaluation of severe asthma in adolescents and adults", section on 'Assessing conditions that mimic asthma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27332862">
         <span class="h1">
          DIFFUSE ASPIRATION BRONCHIOLITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse aspiration bronchiolitis is a poorly defined, occult entity most commonly found in young to middle-aged subjects with identifiable predisposing factors, eg, gastroesophageal reflux disease (GERD), drug abuse, and dysphagia [
         <a href="#rid90">
          90,91
         </a>
         ]. A retrospective study of 20 consecutive patients found that cough, sputum production, dyspnea, and fever in patients with a history of recurrent pneumonia unresponsive to antimicrobial therapy were the most common manifestations [
         <a href="#rid45">
          45
         </a>
         ]. A high index of suspicion is required to make the diagnosis as only 25 percent of patients were clinically suspected to have aspiration as the underlying cause of their lung disease. Chest computed tomography (CT) findings included micronodules and tree-in-bud opacities. Management of these patients should focus on the treatment of GERD and prevention of recurrent aspiration. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3935478">
         <span class="h1">
          DIFFUSE PANBRONCHIOLITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse panbronchiolitis (DPB) is a distinct clinicopathologic syndrome that involves the upper and lower respiratory tracts  (
         <a class="graphic graphic_table graphicRef101928" href="/z/d/graphic/101928.html" rel="external">
          table 1
         </a>
         ). It occurs mainly among the Japanese and is rarely reported outside Southeast Asia. The histologic lesion of DPB is centered on the respiratory bronchiole, and consists of a transmural infiltrate composed of lymphocytes, plasma cells, and distinctive lipid-laden "foamy" macrophages. Patients present in their second to fifth decade with sinusitis, productive cough, breathlessness, and wheezing. The clinical manifestations, diagnostic evaluation, and treatment of diffuse panbronchiolitis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4366.html" rel="external">
          "Diffuse panbronchiolitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Bronchiolitis is a general term used to describe a nonspecific inflammatory injury that primarily affects the
         <strong>
          small airways
         </strong>
         and generally spares the interstitium. The main types are bronchiolitis obliterans (also called constrictive bronchiolitis), acute bronchiolitis, proliferative bronchiolitis, follicular bronchiolitis, respiratory bronchiolitis, airway centered interstitial fibrosis, and diffuse panbronchiolitis. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchiolitis obliterans
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Causes
         </strong>
         – Bronchiolitis obliterans may be caused by inhalation injury, infection, or drugs; associated with organ transplantation, rheumatic disease, or paraneoplastic pemphigus; or may be idiopathic  (
         <a class="graphic graphic_table graphicRef70650" href="/z/d/graphic/70650.html" rel="external">
          table 2
         </a>
         ). Bronchiolitis obliterans syndrome (BOS) is a clinical term that is used after lung or hematopoietic cell transplantation when the patient has airflow limitation but has not had confirmatory lung biopsy. (See
         <a class="local">
          'Causes'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Airflow obstruction and bronchiolitis obliterans'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Evaluation
         </strong>
         – Bronchiolitis obliterans is typically suspected in a patient with the insidious onset of dyspnea and cough, especially when the patient has a predisposing exposure or condition  (
         <a class="graphic graphic_table graphicRef101928" href="/z/d/graphic/101928.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pulmonary function testing (PFT) may be normal or show irreversible airway obstruction with air trapping.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Radiographic findings consistent with bronchiolitis (eg, air trapping, mosaic attenuation, centrilobular nodules, and "v" or "y" shaped branching linear opacities) are more likely to be identified on high-resolution CT (HRCT) scans than on plain chest radiographs, particularly when inspiratory and expiratory images are obtained; however, HRCT may also be normal. (See
         <a class="local">
          'Chest imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Bronchoscopy may exclude diseases with a similar presentation, such as sarcoidosis and hypersensitivity pneumonitis. (See
         <a class="local">
          'Bronchoscopy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diagnosis
         </strong>
         – In most patients, open or thoracoscopic lung biopsy is required, although tissue confirmation may not be necessary in patients with a clear predisposition (eg, known inhalational exposure or prior lung or hematopoietic cell transplantation) and typical HRCT features. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of bronchiolitis obliterans includes asthma, COPD, hypersensitivity pneumonitis (HP), sarcoidosis, bronchocentric granulomatosis, diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH), and hypereosinophilic obliterative bronchiolitis. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment
         </strong>
         – The
         <strong>
         </strong>
         optimal treatment of bronchiolitis obliterans unrelated to transplantation has not been determined. Symptomatic therapy with cough suppressants (eg,
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         ,
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         ) may be beneficial, and inhaled bronchodilators may alleviate cough and/or dyspnea in some patients. (See
         <a class="local">
          'Symptom-based and supportive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Potential culprit exposures or medications  (
         <a class="graphic graphic_table graphicRef70650" href="/z/d/graphic/70650.html" rel="external">
          table 2
         </a>
         ) should be stopped in any patient who develops bronchiolitis. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with cryptogenic bronchiolitis obliterans (constrictive), we suggest a trial of a macrolide antibiotic (eg,
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We typically use a low dose for a three- to six-month trial and continue therapy if lung function stabilizes or improves. (See
         <a class="local">
          'Pharmacotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The role of systemic glucocorticoid therapy
         <strong>
          in nontransplant
         </strong>
         -related bronchiolitis obliterans is unclear. Most case series have not found clear benefit. (See
         <a class="local">
          'Pharmacotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other bronchiolar disorders
         </strong>
         – The clinical, imaging, histopathologic features of the other chronic bronchiolar disorders are listed in the table  (
         <a class="graphic graphic_table graphicRef101928" href="/z/d/graphic/101928.html" rel="external">
          table 1
         </a>
         ). Proliferative, follicular, and respiratory bronchiolitis, and diffuse panbronchiolitis are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">
          "Overview of pleuropulmonary diseases associated with rheumatoid arthritis", section on 'Follicular bronchiolitis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4301.html" rel="external">
          "Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis", section on 'Follicular bronchiolitis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4319.html" rel="external">
          "Respiratory bronchiolitis-associated interstitial lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4366.html" rel="external">
          "Diffuse panbronchiolitis"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med 2003; 168:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr. Overview of bronchiolitis. Clin Chest Med 1993; 14:607.
          </a>
         </li>
         <li class="breakAll">
          King TE Jr. Bronchiolitis. In: Interstitial Lung Disease, 5th ed, Schwarz MI, King TE Jr (Eds), People's Medical Publishing House, Shelton, CT, USA 2011. p.1003.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J Med 2014; 370:1820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cordier JF. Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis. Thorax 2007; 62:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swaminathan AC, Carney JM, Tailor TD, Palmer SM. Overview and Challenges of Bronchiolar Disorders. Ann Am Thorac Soc 2020; 17:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myers JL, Colby TV. Pathologic manifestations of bronchiolitis, constrictive bronchiolitis, cryptogenic organizing pneumonia, and diffuse panbronchiolitis. Clin Chest Med 1993; 14:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg K, Lynch DA, Newell JD, King TE Jr. Proliferative and constrictive bronchiolitis: classification and radiologic features. AJR Am J Roentgenol 1994; 162:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couture C, Colby TV. Histopathology of bronchiolar disorders. Semin Respir Crit Care Med 2003; 24:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hendrick DJ. "Popcorn worker's lung" in Britain in a man making potato crisp flavouring. Thorax 2008; 63:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rooy FG, Rooyackers JM, Prokop M, et al. Bronchiolitis obliterans syndrome in chemical workers producing diacetyl for food flavorings. Am J Respir Crit Care Med 2007; 176:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsiue TR, Guo YL, Chen KW, et al. Dose-response relationship and irreversible obstructive ventilatory defect in patients with consumption of Sauropus androgynus. Chest 1998; 113:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockey JE, Hilbert TJ, Levin LP, et al. Airway obstruction related to diacetyl exposure at microwave popcorn production facilities. Eur Respir J 2009; 34:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harber P, Levine J, Bansal S. How frequently should workplace spirometry screening be performed?: optimization via analytic models. Chest 2009; 136:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Obliterative bronchiolitis in workers in a coffee-processing facility - Texas, 2008-2012. MMWR Morb Mortal Wkly Rep 2013; 62:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanei M, Tazelaar HD, Chilosi M, et al. An international collaborative pathologic study of surgical lung biopsies from mustard gas-exposed patients. Respir Med 2008; 102:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King MS, Eisenberg R, Newman JH, et al. Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan. N Engl J Med 2011; 365:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nett RJ, Harvey RR, Cummings KJ. Occupational Bronchiolitis: An Update. Clin Chest Med 2020; 41:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duling MG, LeBouf RF, Cox-Ganser JM, et al. Environmental characterization of a coffee processing workplace with obliterative bronchiolitis in former workers. J Occup Environ Hyg 2016; 13:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park RM, Gilbert SJ. Pulmonary Impairment and Risk Assessment in a Diacetyl-Exposed Population: Microwave Popcorn Workers. J Occup Environ Med 2018; 60:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brass DM, Gwinn WM, Valente AM, et al. The Diacetyl-Exposed Human Airway Epithelial Secretome: New Insights into Flavoring-Induced Airways Disease. Am J Respir Cell Mol Biol 2017; 56:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schier JG, Meiman JG, Layden J, et al. Severe Pulmonary Disease Associated with Electronic-Cigarette-Product Use - Interim Guidance. MMWR Morb Mortal Wkly Rep 2019; 68:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen JG, Flanigan SS, LeBlanc M, et al. Flavoring Chemicals in E-Cigarettes: Diacetyl, 2,3-Pentanedione, and Acetoin in a Sample of 51 Products, Including Fruit-, Candy-, and Cocktail-Flavored E-Cigarettes. Environ Health Perspect 2016; 124:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gotts JE, Jordt SE, McConnell R, Tarran R. What are the respiratory effects of e-cigarettes? BMJ 2019; 366:l5275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blount BC, Karwowski MP, Shields PG, et al. Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI. N Engl J Med 2020; 382:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butt YM, Smith ML, Tazelaar HD, et al. Pathology of Vaping-Associated Lung Injury. N Engl J Med 2019; 381:1780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parambil JG, Yi ES, Ryu JH. Obstructive bronchiolar disease identified by CT in the non-transplant population: analysis of 29 consecutive cases. Respirology 2009; 14:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hariri LP, Flashner BM, Kanarek DJ, et al. E-Cigarette Use, Small Airway Fibrosis, and Constrictive Bronchiolitis. NEJM Evid 2022; 1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garshick E, Abraham JH, Baird CP, et al. Respiratory Health after Military Service in Southwest Asia and Afghanistan. An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc 2019; 16:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis CW, Lopez CL, Bell AJ, et al. The Severity of Functional Small Airway Disease in Military Personnel with Constrictive Bronchiolitis as Measured by Quantitative Computed Tomography. Am J Respir Crit Care Med 2022; 206:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falvo MJ, Sotolongo AM, Osterholzer JJ, et al. Consensus Statements on Deployment-Related Respiratory Disease, Inclusive of Constrictive Bronchiolitis: A Modified Delphi Study. Chest 2023; 163:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devouassoux G, Cottin V, Lioté H, et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009; 33:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papiris SA, Malagari K, Manali ED, et al. Bronchiolitis: adopting a unifying definition and a comprehensive etiological classification. Expert Rev Respir Med 2013; 7:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreiss K. Occupational causes of constrictive bronchiolitis. Curr Opin Allergy Clin Immunol 2013; 13:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devakonda A, Raoof S, Sung A, et al. Bronchiolar disorders: a clinical-radiological diagnostic algorithm. Chest 2010; 137:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pipavath SJ, Lynch DA, Cool C, et al. Radiologic and pathologic features of bronchiolitis. AJR Am J Roentgenol 2005; 185:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hwang JH, Kim TS, Lee KS, et al. Bronchiolitis in adults: pathology and imaging. J Comput Assist Tomogr 1997; 21:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch DA. Imaging of small airways disease and chronic obstructive pulmonary disease. Clin Chest Med 2008; 29:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee GM, Carroll MB, Galvin JR, Walker CM. Mosaic Attenuation Pattern: A Guide to Analysis with HRCT. Radiol Clin North Am 2022; 60:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen SP, Lynch DA, Brown KK, et al. High-resolution CT features of severe asthma and bronchiolitis obliterans. Clin Radiol 2002; 57:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Oliveira MR, Dias OM, Amaral AF, et al. Diffuse cystic lung disease as the primary tomographic manifestation of bronchiolitis: A case series. Pulmonology 2020; 26:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch JP 3rd, Weigt SS, DerHovanessian A, et al. Obliterative (constrictive) bronchiolitis. Semin Respir Crit Care Med 2012; 33:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myong NH, Shin DH, Lee KY. A clinicopathologic study on three cases of constrictive bronchiolitis. J Korean Med Sci 2001; 16:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visscher DW, Myers JL. Bronchiolitis: the pathologist's perspective. Proc Am Thorac Soc 2006; 3:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu X, Yi ES, Ryu JH. Diffuse aspiration bronchiolitis: analysis of 20 consecutive patients. J Bras Pneumol 2015; 41:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr LL, Chung JH, Duarte Achcar R, et al. The clinical course of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Chest 2015; 147:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nassar AA, Jaroszewski DE, Helmers RA, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a systematic overview. Am J Respir Crit Care Med 2011; 184:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorshtein A, Gross DJ, Barak D, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entity. Cancer 2012; 118:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trisolini R, Valentini I, Tinelli C, et al. DIPNECH: Association Between Histopathology and Clinical Presentation. Lung 2016; 194:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chassagnon G, Favelle O, Marchand-Adam S, et al. DIPNECH: when to suggest this diagnosis on CT. Clin Radiol 2015; 70:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callahan SJ, Vranic A, Flors L, et al. Sporadic Obliterative Bronchiolitis: Case Series and Systematic Review of the Literature. Mayo Clin Proc Innov Qual Outcomes 2019; 3:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akpinar-Elci M, Travis WD, Lynch DA, Kreiss K. Bronchiolitis obliterans syndrome in popcorn production plant workers. Eur Respir J 2004; 24:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azuma A, Kudoh S. Securing the safety and efficacy of macrolide therapy for chronic small airway diseases. Intern Med 2005; 44:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinberger M, Lesser D. Diffuse panbronchiolitis: A progressive fatal lung disease that is curable with azithromycin, but only if diagnosed! Pediatr Pulmonol 2019; 54:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weng D, Wu Q, Chen XQ, et al. Azithromycin treats diffuse panbronchiolitis by targeting T cells via inhibition of mTOR pathway. Biomed Pharmacother 2019; 110:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann JM, Sha KK, Kline G, et al. World Trade Center dyspnea: bronchiolitis obliterans with functional improvement: a case report. Am J Ind Med 2005; 48:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraft M, Mortenson RL, Colby TV, et al. Cryptogenic constrictive bronchiolitis. A clinicopathologic study. Am Rev Respir Dis 1993; 148:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortot AB, Cottin V, Miossec P, et al. Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept. Respir Med 2005; 99:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu X, Lee JS, Pianosi PT, Ryu JH. Aspiration-related pulmonary syndromes. Chest 2015; 147:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendez BM, Davis CS, Weber C, et al. Gastroesophageal reflux disease in lung transplant patients with cystic fibrosis. Am J Surg 2012; 204:e21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reder NP, Davis CS, Kovacs EJ, Fisichella PM. The diagnostic value of gastroesophageal reflux disease (GERD) symptoms and detection of pepsin and bile acids in bronchoalveolar lavage fluid and exhaled breath condensate for identifying lung transplantation patients with GERD-induced aspiration. Surg Endosc 2014; 28:1794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis CS, Mendez BM, Flint DV, et al. Pepsin concentrations are elevated in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis after lung transplantation. J Surg Res 2013; 185:e101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welsh CH, Wang TS, Lyu DM, et al. An international ISHLT/ATS/ERS clinical practice guideline: summary for clinicians. Bronchiolitis obliterans syndrome complicating lung transplantation. Ann Am Thorac Soc 2015; 12:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbassi-Ghadi N, Kumar S, Cheung B, et al. Anti-reflux surgery for lung transplant recipients in the presence of impedance-detected duodenogastroesophageal reflux and bronchiolitis obliterans syndrome: a study of efficacy and safety. J Heart Lung Transplant 2013; 32:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chambers DC, Cherikh WS, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant 2019; 38:1042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heo JY, Lee JE, Kim HK, Choe KW. Acute lower respiratory tract infections in soldiers, South Korea, April 2011-March 2012. Emerg Infect Dis 2014; 20:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebnöther M, Schoenenberger RA, Perruchoud AP, et al. Severe bronchiolitis in acute Mycoplasma pneumoniae infection. Virchows Arch 2001; 439:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cha SI, Shin KM, Kim M, et al. Mycoplasma pneumoniae bronchiolitis in adults: clinicoradiologic features and clinical course. Scand J Infect Dis 2009; 41:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimatsu Y, Fujimori K. [Pulmonary complications in adult measles]. Kansenshogaku Zasshi 1999; 73:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romero S, Barroso E, Gil J, et al. Follicular bronchiolitis: clinical and pathologic findings in six patients. Lung 2003; 181:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Exley CM, Suvarna SK, Matthews S. Follicular bronchiolitis as a presentation of HIV. Clin Radiol 2006; 61:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shipe R, Lawrence J, Green J, Enfield K. HIV-associated follicular bronchiolitis. Am J Respir Crit Care Med 2013; 188:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bezrodnik L, Caldirola MS, Seminario AG, et al. Follicular bronchiolitis as phenotype associated with CD25 deficiency. Clin Exp Immunol 2014; 175:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aerni MR, Vassallo R, Myers JL, et al. Follicular bronchiolitis in surgical lung biopsies: clinical implications in 12 patients. Respir Med 2008; 102:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costa-Carvalho BT, Wandalsen GF, Pulici G, et al. Pulmonary complications in patients with antibody deficiency. Allergol Immunopathol (Madr) 2011; 39:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camarasa Escrig A, Amat Humaran B, Sapia S, León Ramírez JM. Follicular bronchiolitis associated with common variable immunodeficiency. Arch Bronconeumol 2013; 49:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howling SJ, Hansell DM, Wells AU, et al. Follicular bronchiolitis: thin-section CT and histologic findings. Radiology 1999; 212:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryu JH. Classification and approach to bronchiolar diseases. Curr Opin Pulm Med 2006; 12:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marquette D, Diot E, de Muret A, et al. Chronic bronchiolitis in ankylosing spondylitis. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tashtoush B, Okafor NC, Ramirez JF, Smolley L. Follicular Bronchiolitis: A Literature Review. J Clin Diagn Res 2015; 9:OE01.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aerni MR, Vassallo R, Ryu JH. Successful treatment of follicular bronchiolitis with macrolide. Chest 2005; 128:428S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yousem SA, Dacic S. Idiopathic bronchiolocentric interstitial pneumonia. Mod Pathol 2002; 15:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yi XH, Chu HQ, Cheng XM, et al. Idiopathic airway-centered interstitial fibrosis: report of two cases. Chin Med J (Engl) 2007; 120:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Churg A, Myers J, Suarez T, et al. Airway-centered interstitial fibrosis: a distinct form of aggressive diffuse lung disease. Am J Surg Pathol 2004; 28:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Carvalho ME, Kairalla RA, Capelozzi VL, et al. Centrilobular fibrosis: a novel histological pattern of idiopathic interstitial pneumonia. Pathol Res Pract 2002; 198:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukuoka J, Franks TJ, Colby TV, et al. Peribronchiolar metaplasia: a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease: clinicopathologic features of 15 cases. Am J Surg Pathol 2005; 29:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pradere P, Gauvain C, Danel C, et al. Airway-Centered Fibroelastosis: A Distinct Entity. Chest 2016; 149:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi T, Inoue H, Mio T. Hypereosinophilic obliterative bronchiolitis clinically mimicking diffuse panbronchiolitis: four-year follow-up. Intern Med 2015; 54:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cordier JF, Cottin V, Khouatra C, et al. Hypereosinophilic obliterative bronchiolitis: a distinct, unrecognised syndrome. Eur Respir J 2013; 41:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuse T, Oka T, Kida K, Fukuchi Y. Importance of diffuse aspiration bronchiolitis caused by chronic occult aspiration in the elderly. Chest 1996; 110:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes TW, Vassallo R, Tazelaar HD, et al. Diffuse bronchiolar disease due to chronic occult aspiration. Mayo Clin Proc 2006; 81:172.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4323 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14644923" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Bronchiolar disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8313665" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Overview of bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8313665" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Overview of bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24806161" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Obliterative bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17600295" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31860801" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Overview and Challenges of Bronchiolar Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8313666" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pathologic manifestations of bronchiolitis, constrictive bronchiolitis, cryptogenic organizing pneumonia, and diffuse panbronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8140994" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Proliferative and constrictive bronchiolitis: classification and radiologic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16088569" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Histopathology of bronchiolar disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18308961" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : "Popcorn worker's lung" in Britain in a man making potato crisp flavouring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17541015" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Bronchiolitis obliterans syndrome in chemical workers producing diacetyl for food flavorings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9440571" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Dose-response relationship and irreversible obstructive ventilatory defect in patients with consumption of Sauropus androgynus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19567602" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Airway obstruction related to diacetyl exposure at microwave popcorn production facilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19411294" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : How frequently should workplace spirometry screening be performed?: optimization via analytic models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23615673" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Obliterative bronchiolitis in workers in a coffee-processing facility - Texas, 2008-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18339530" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : An international collaborative pathologic study of surgical lung biopsies from mustard gas-exposed patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21774710" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33153686" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Occupational Bronchiolitis: An Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27105025" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Environmental characterization of a coffee processing workplace with obliterative bronchiolitis in former workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29443707" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pulmonary Impairment and Risk Assessment in a Diacetyl-Exposed Population: Microwave Popcorn Workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28248570" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The Diacetyl-Exposed Human Airway Epithelial Secretome: New Insights into Flavoring-Induced Airways Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31513561" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Severe Pulmonary Disease Associated with Electronic-Cigarette-Product Use - Interim Guidance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26642857" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Flavoring Chemicals in E-Cigarettes: Diacetyl, 2,3-Pentanedione, and Acetoin in a Sample of 51 Products, Including Fruit-, Candy-, and Cocktail-Flavored E-Cigarettes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31570493" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : What are the respiratory effects of e-cigarettes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31860793" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31577870" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pathology of Vaping-Associated Lung Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19210653" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Obstructive bronchiolar disease identified by CT in the non-transplant population: analysis of 29 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37122361" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : E-Cigarette Use, Small Airway Fibrosis, and Constrictive Bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31368802" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Respiratory Health after Military Service in Southwest Asia and Afghanistan. An Official American Thoracic Society Workshop Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35608541" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The Severity of Functional Small Airway Disease in Military Personnel with Constrictive Bronchiolitis as Measured by Quantitative Computed Tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36343686" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Consensus Statements on Deployment-Related Respiratory Disease, Inclusive of Constrictive Bronchiolitis: A Modified Delphi Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19129282" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23734650" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Bronchiolitis: adopting a unifying definition and a comprehensive etiological classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23407121" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Occupational causes of constrictive bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20371529" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Bronchiolar disorders: a clinical-radiological diagnostic algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16037505" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Radiologic and pathologic features of bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9386284" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Bronchiolitis in adults: pathology and imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18267190" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Imaging of small airways disease and chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36202482" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Mosaic Attenuation Pattern: A Guide to Analysis with HRCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12475532" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : High-resolution CT features of severe asthma and bronchiolitis obliterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32107182" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Diffuse cystic lung disease as the primary tomographic manifestation of bronchiolitis: A case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23001805" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Obliterative (constrictive) bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11306739" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A clinicopathologic study on three cases of constrictive bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16493150" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Bronchiolitis: the pathologist's perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25972969" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Diffuse aspiration bronchiolitis: analysis of 20 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25275948" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The clinical course of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21471097" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a systematic overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21751183" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26880164" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : DIPNECH: Association Between Histopathology and Clinical Presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25465294" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : DIPNECH: when to suggest this diagnosis on CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30899912" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Sporadic Obliterative Bronchiolitis: Case Series and Systematic Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15332401" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Bronchiolitis obliterans syndrome in popcorn production plant workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15805698" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Securing the safety and efficacy of macrolide therapy for chronic small airway diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30609307" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Diffuse panbronchiolitis: A progressive fatal lung disease that is curable with azithromycin, but only if diagnosed!
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30530046" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Azithromycin treats diffuse panbronchiolitis by targeting T cells via inhibition of mTOR pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16094618" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : World Trade Center dyspnea: bronchiolitis obliterans with functional improvement: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8214931" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Cryptogenic constrictive bronchiolitis. A clinicopathologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15763460" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25732447" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Aspiration-related pulmonary syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22921151" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Gastroesophageal reflux disease in lung transplant patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24414458" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The diagnostic value of gastroesophageal reflux disease (GERD) symptoms and detection of pepsin and bile acids in bronchoalveolar lavage fluid and exhaled breath condensate for identifying lung transplantation patients with GERD-induced aspiration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23845868" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Pepsin concentrations are elevated in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25635657" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : An international ISHLT/ATS/ERS clinical practice guideline: summary for clinicians. Bronchiolitis obliterans syndrome complicating lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23540400" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Anti-reflux surgery for lung transplant recipients in the presence of impedance-detected duodenogastroesophageal reflux and bronchiolitis obliterans syndrome: a study of efficacy and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31548030" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24750820" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Acute lower respiratory tract infections in soldiers, South Korea, April 2011-March 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11787856" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Severe bronchiolitis in acute Mycoplasma pneumoniae infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19412880" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Mycoplasma pneumoniae bronchiolitis in adults: clinicoradiologic features and clinical course.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10481398" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : [Pulmonary complications in adult measles].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14749935" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Follicular bronchiolitis: clinical and pathologic findings in six patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16843757" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Follicular bronchiolitis as a presentation of HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23947519" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : HIV-associated follicular bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24116927" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Follicular bronchiolitis as phenotype associated with CD25 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17997299" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Follicular bronchiolitis in surgical lung biopsies: clinical implications in 12 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21339034" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Pulmonary complications in patients with antibody deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22963957" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Follicular bronchiolitis associated with common variable immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10478225" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Follicular bronchiolitis: thin-section CT and histologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16456385" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Classification and approach to bronchiolar diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24284298" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Chronic bronchiolitis in ankylosing spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26500941" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Follicular Bronchiolitis: A Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Successful treatment of follicular bronchiolitis with macrolide
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12429793" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Idiopathic bronchiolocentric interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17531132" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Idiopathic airway-centered interstitial fibrosis: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14707865" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Airway-centered interstitial fibrosis: a distinct form of aggressive diffuse lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12440779" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Centrilobular fibrosis: a novel histological pattern of idiopathic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15958861" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Peribronchiolar metaplasia: a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease: clinicopathologic features of 15 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26836939" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Airway-Centered Fibroelastosis: A Distinct Entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25948354" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Hypereosinophilic obliterative bronchiolitis clinically mimicking diffuse panbronchiolitis: four-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23258778" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Hypereosinophilic obliterative bronchiolitis: a distinct, unrecognised syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8915236" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Importance of diffuse aspiration bronchiolitis caused by chronic occult aspiration in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16471070" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Diffuse bronchiolar disease due to chronic occult aspiration.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
